ASCO 2026
Could GLP-1 drugs slow cancer progression?
Clinical Takeaway: In patients with early-stage solid tumors and an indication for glucose-lowering therapy, GLP-1 receptor agonists may be a reasonable option and were associated with lower risk of metastatic progression compared with DPP-4 inhibitors, without new safety signals—but prospective trials are needed before routine oncologic use.
GLP-1 RAs are already reshaping obesity and diabetes care; emerging evidence now suggests they may also influence cancer biology and disease progression.
Researchers presenting at the 2026 ASCO Annual Meeting analyzed outcomes from more than 10,000 patients with seven obesity-associated solid tumors to evaluate whether GLP-1 RAs may reduce cancer progression. Using a propensity-matched design, investigators compared patients treated with GLP-1 RAs after cancer diagnosis against matched patients receiving other antidiabetic therapies, including DPP-4 inhibitors.
The study found consistent associations between GLP-1 RA use and lower rates of progression to metastatic disease across several tumor types. Among patients with stage III non–small cell lung cancer, GLP-1 RA exposure was associated with roughly a 50% lower likelihood of progression to stage IV disease. In breast cancer, progression risk was reduced by approximately 43% in treated patients. Investigators also reported favorable trends in colorectal, liver, and other obesity-associated cancers.
Although the mechanism remains unclear, researchers suggested the benefit may extend beyond weight loss alone, potentially involving direct effects on tumor metabolism and inflammation. Lead investigator Dr. Mark David Orland noted that the observed anticancer effect was “likely due to the drug itself.”
Experts cautioned that the findings are observational and hypothesis-generating, not proof of causality. Still, the consistency of benefit across multiple tumor types is likely to intensify interest in prospective oncology trials evaluating GLP-1–based therapies as adjuncts to cancer treatment.
Source: ASCO Annual Meeting 2026. Abstract 3143: Can GLP-1 receptor agonists mitigate cancer progression? A propensity-matched analysis across seven solid tumors